Innovation Pharmaceuticals Inc.
IPIX
$0.0002
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.31% | -24.72% | -1.77% | 11.75% | 11.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.55% | -56.63% | -54.67% | -47.50% | -38.09% |
| Operating Income | 61.44% | 56.51% | 54.90% | 47.71% | 38.27% |
| Income Before Tax | 59.15% | 55.01% | 48.46% | 53.12% | 56.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.15% | 55.01% | 48.46% | 53.12% | 56.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.15% | 55.01% | 48.46% | 53.12% | 56.54% |
| EBIT | 61.44% | 56.51% | 54.90% | 47.71% | 38.27% |
| EBITDA | 65.40% | 59.76% | 57.57% | 49.92% | 39.80% |
| EPS Basic | 59.52% | 56.64% | 58.19% | 61.83% | 66.13% |
| Normalized Basic EPS | 60.00% | 56.67% | 60.18% | 63.40% | 65.52% |
| EPS Diluted | 59.52% | 56.64% | 58.19% | 61.83% | 66.13% |
| Normalized Diluted EPS | 60.00% | 56.67% | 60.18% | 63.40% | 65.52% |
| Average Basic Shares Outstanding | -1.71% | 0.07% | 18.61% | 20.77% | 25.01% |
| Average Diluted Shares Outstanding | -1.71% | 0.07% | 18.61% | 20.77% | 25.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.09% | -- | -- | -- | -- |